UTI India Dynamic Equity Fund

May 2018 Review

Commentary on Equity Markets

The MSCI India Index started the month at 18.99 and closed at 18.43 decreasing by 3% over the month. As per latest data, FIIs were net sellers in Equity with outflow of USD 1.20 Bn compared to outflow of USD 0.97 Bn seen last month. FIIs sold USD 2.58 Bn in Indian debt compared to outflow of USD 1.77 Bn last month. Domestic Institutions were net buyers in equities with net buying of USD 2.02 Bn in the month.

Commodities and Inflation

NYMEX Crude Oil prices fell by ~2.23% from the previous month levels, ending at 67.04 per barrel; the prices were higher by ~38.7% yoy. LMEX closed at 3350.6 higher by 1.54% over the month (higher ~21.43% yoy). Gold prices closed at USD 1304/oz lower by ~0.95% over the previous month (higher by ~3.13% yoy). The USD Index strengthened vs. other currencies with USD rising ~2.33% over the month; over the year the USD Index was lower by ~3.04%.

April CPI at 4.88% came in higher than 4.28% seen in March. Higher global commodity prices (oil and gold) and improvement in domestic growth sentiment in H2FY18 imply both cost push and demand pull inflationary pressures across segments. While food and fuel inflation marked moderate inch up in prices, the momentum remained robust in core inflation (largely reflecting demand side inflation in line with the uptick seen in nominal and rural wages recently). Core inflation neared RBI's upper comfort band level of 6%, coming in at an almost 4 year high at 5.92% vs 5.37% in March. Core inflation ex-transport & communication remained elevated at 5.11%. The last 6 months CPI has averaged 4.7% while core has averaged 5.3% (above RBI's 4% comfort). The readings are likely to remain on an uptrend with the seasonal reversal in food prices, elevated oil prices and sticky core inflation.

Markets & Real Economy

Mar IIP at 4.4% ended the fiscal year on a tepid note adversely impacted by a strong base. Mining, Manufacturing & Electricity grew 2.8%, 4.4% & 5.9% respectively. Capital goods (-1.8% YoY) contracted based on a strong base and contraction in items such as 'Material handling, lifting and hoisting equipment', 'Generators/ Alternators', and 'Printing machinery'. Primary goods (2.9%) and Intermediate goods (2.1%) remained weak. Non durables (10.9%) grew strongly while Infrastructure/construction goods (8.8%) remained healthy supported by items such as cement. Consumer durables (2.9%) came in muted. FY18 IIP at 4.3% remained lower than 4.6% in FY17; recovering from re-monetization however taking a set back with GST implementation adjustments.

As per the latest RBI data, Forex reserves position declined to USD 412.82 Bn over the month. The Rupee weakened by ~1.17% closing at 67.5250 Rs/USD vs. 66.7403 Rs/USD last month.

Sector-wise Performance

Key outperforming sector during the month was Banking & Financial Services. The outperformance of the sector has been driven by private sector banks, especially retail focused banks, which continue to show healthy growth while at the same time maintaining extremely healthy asset quality. At the time when public sector banks are facing significant deterioration in asset quality with bad loan write-offs leading to losses in a few banks, the ability of these banks to finance the funding needs to a growing economy are severely hampered. This provides an opportunity for private sector banks with adequate growth capital at their disposal to keep gaining market share, a trend that has already been playing out over the last few years and has gained momentum in recent times. We remain positive on the sector given significant under-penetration of financial services in India and significant growth potential over the long term. Within the sector, we have always stressed on our preference for private sector banks in the portfolio and will continue to avoid investing in public sector banks going forward as well.

Key underperforming sector during the month was Healthcare. Companies within the sector have been facing a challenging environment over the last couple of years primarily within the US market. Channel consolidation in the US market has led to double digit price erosion in the market as the bargaining power of the pharmaceutical companies has weakened. While in normal course, such price erosion in existing portfolio is compensated by new product launches, the same has not played out in the recent past as a number of companies have been facing US FDA compliance issues on their manufacturing facilities. While these have led to muted growth over the past year, some indications of a gradual pick-up have been visible in the most recent quarterly results where a number of companies have shown sequential improvement in their revenues, indicating that the worst is behind and a gradual pick-up is expected going ahead. INR weakness is also a positive for export oriented pharmaceutical companies as it leads to better realizations and improves their ability to absorb pricing pressures. On the domestic front, there are a number of growth drivers in place as spend on healthcare in India is significantly lower than global standards and shall rise over time. This is expected to drive growth for the domestic companies, especially those with focus on chronic lifestyle diseases. Given the underperformance of the sector, valuations have become extremely attractive and present an opportunity to generate healthy returns over the long term. We are positive on the sector.

Market Outlook

Imposition of sanctions on Iran by the US has created geo-political uncertainty leading to sharp rise in crude oil prices, which were already on an uptrend. However, Russia and Saudi Arabia have indicated that they may increase oil supply going ahead which may keep crude oil prices under check in the near term. A sharp rise in crude oil prices is a concern for India as it may lead to worsening of Current Account Deficit and increase in inflation. However, in case OPEC increases its crude oil output during the second half of the year, it will be positive for India from a macro economic perspective. A weak global sentiment has led to outflow of funds from emerging markets, including India, putting pressure on the currency as well. The depreciation of the INR was anticipated as the currency has been in an overvalued zone for quite some time. Post the recent depreciation, the INR seems to be in the fair value zone now and shall remain near current levels going forward, although there may be some volatility in the near term. There are green shoots to growth visible in Q3 results, which appear to have become stronger in Q4. India has seen muted growth over the last three to four years and there is an expectation of a turnaround in both economic growth and corporate earnings. Valuations, which had become expensive post the sharp rally in the market, have cooled down post the correction witnessed over the last three months, especially in the mid cap segment. We remain confident about the long term growth potential in the Indian economy and feel that the ongoing correction offers an opportunity to increase exposure in select high quality sectors and companies

	USD Institutional	USD RDR	USD Retail	Euro	Euro Retail	GBP RDR
ISIN	IE00BYPC7R45	IE00BYPC7S51	IE00BYPC7Q38	IE00BYPC7T68	IE00BDH6RQ67	IE00BDH6RR74

This report has been supplied solely for use by the person to whom it is made available. The Company makes no representation with regard to the completeness and accuracy of the data or information contained herein, and it accepts no responsibility and disclaims all liability for loss or damage whatsoever suffered or incurred by any other person resulting from the use of, or reliance upon, the data or information contained herein. Certain information in this document has been provided by third-party sources and, although believed to be reliable, it has not been independently verified and its accuracy or completeness cannot be guaranteed. The content of the statement are for illustration/ information & discussion purpose only without regard to the specific objectives, financial situation and particular needs of any specific person who may receive this statement, such person may wish to seek advice from a financial adviser before committing to invest in any of the Fund. If such person chooses not to do so, he should consider carefully whether the investment is suitable for him.

Austria

Erste Bank der oesterreichischen Sparkassen AG (the "Paying Agent") having its registered office at OE 01980869, AM Belvedere 1, A-1100 Wien, Austria has been appointed as the paying agent and information agent in Austria in accordance with sec. 141 para 1 of the IFA 2011. Investors may seek further information as to the subscription and redemption procedure applicable to the Fund from the Paying Agent.

Finland

The Funds are established under the laws of the Ireland and are marketed in Finland in accordance with Chapter XI of Directive 2009/65/EC as transposed into national legislation, including Section 128 of the Finnish Act on Mutual Funds (48/1999, as amended) unless otherwise stated herein.

Germany

The Bundesanstalt für Finanzdienstleistungsaufsicht (Federal Agency for Financial Services Supervision) has been notified pursuant to Sec. 132 Investmentgesetz (Investment Act) of the intention to publicly distribute Shares of the Fund in the Federal Republic of Germany. The legal documents can be obtained in German, free of charge, from the information agent. The Information Agent in Germany is GerFIS - German Fund Information Service UG (haftungsbeschränkt), Zum Eichhagen 4, 21382 Brietlingen, Germany.

Guernsey

UTI International Ltd, Guernsey (UTI IL) is a regulated entity in Guernsey, governed by Guernsey law, and is under the Protection of Investors (Bailiwick of Guernsey) Law 1987.

Hong Kong

The distribution of this document/ the prospectus / KIID or any marketing material ("this material") of the Fund ("the Fund"), may only be made in Hong Kong in circumstances that do not constitute an issue, invitation or offer to the public under the Hong Kong Securities and Futures Ordinance ("Securities and Futures Ordinance"). This material is confidential to you. The contents of this material have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offering of the shares described in this material. If you are in any doubt about any of the contents of this material, you should obtain independent professional advice. The Fund has not been authorized by the Securities and Futures Commission in Hong Kong pursuant to Section 104 of the Securities and Futures Ordinance nor has the offering memorandum been registered by the Registrar of Companies in Hong Kong pursuant to the Hong Kong Companies Ordinance ("Companies Ordinance"). Accordingly, unless permitted by the Securities and Futures Ordinance no person may issue or have in its possession for issue in Hong Kong this material or any other invitation, advertisement or document relating to the Participating Shares interests in the Fund to anyone other than (1) to professional investors within the meaning of the Securities and Futures Ordinance and any rules made there under, (2) to persons and in circumstances which do not constitute an invitation or offer to the public within the meaning of the Securities and Futures Ordinance or the Companies Ordinance, or (3) otherwise pursuant to, and in accordance with the conditions of, any other applicable provisions of the Securities and Futures Ordinance and the Companies Ordinance.

Ireland

The Fund is an open-ended investment company with variable capital incorporated with limited liability in Ireland under the Companies Acts, 1963 to 2012 with registration number 516063 and established as an undertaking for collective investment in transferable securities pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011). The Fund is both authorised and supervised by the Central Bank. Authorisation of the Fund by the Central Bank shall not constitute a warranty as to the performance of the Fund and the Central Bank shall not be liable for the performance or default of the Fund. The authorisation of the Fund is not an endorsement or guarantee of the Fund by the Central Bank and the Central Bank is not responsible for the contents of the Prospectus of the Fund.

Singapore

The Fund is a recognised scheme under the Securities and Futures Act, Chapter 289 of Singapore ("SFA"). A copy of the Singapore Prospectus has been lodged with and registered by the Monetary Authority of Singapore ("MAS"). Investors from Singapore must read the Singapore prospectus and the product highlights sheet before making any investment decision. The MAS assumes no responsibility for the contents of the Singapore Prospectus. Registration of the Singapore Prospectus by the MAS does not imply that the SFA or any other legal or regulatory requirements have been complied with. The MAS has not, in any way, considered the investment merits of the Company. The distribution of this Singapore Prospectus and the offering or sale of the Shares in the Company in some jurisdictions may be restricted or prohibited. Persons who have possession of the Singapore Prospectus of the Fund must inform themselves about and observe such restrictions or prohibitions.

Switzerland

The Company is authorized for public distribution in and from Switzerland by the Swiss Financial Market Supervisory Authority ("FINMA"). Investors from Switzerland should read the Consolidated Prospectus for use solely in Switzerland. The representative and paying agent in Switzerland is RBC Investor Services Bank S.A., Esch-sur-Alzette, Zurich Branch, Bleicherweg 7, CH-8027 Zurich, Switzerland (the "Representative"). In Switzerland, the funds prospectus, Key Investor Information Document (KIID), the articles of association, the annual and semi-annual reports may be obtained free of charge from the Representative. In respect of the units distributed in and from Switzerland, the places of performance and jurisdiction is the registered office of the Representative.

Sweden

The Funds are registered in Sweden pursuant to Chapter 1, Section 7 of the Swedish Investment Funds Act ((Sw. lag (2004:46) om värdepappersfonder) and the Funds may be marketed and distributed in Sweden. Prospectuses, key investor information document (KIID), most recent annual reports and, where applicable, half-yearly reports published thereafter, are provided or sent free of charge to any investor intending to invest in the Funds. Prospectuses and KIID of the Funds may also be obtained from the Fund's Paying Agent in Sweden at MFEX Mutual Funds Exchange AB, Grev Turegatan 19, Box 5378, SE-114 38 Stockholm, Sweden. Tel: +46 (0)8 559 03 600 / Fax:+46 (0)8 545 186 29.

Spain

The UTI Goldfinch Funds Plc, SICAV is duly registered in the CNMV official registry of foreign collective investment institutions as authorised to be marketed to the public in Spain with number 1668. In Spain, any investment must be made through the authorised distributors and on the basis of the information contained in the mandatory documentation that must be received from the authorised distributor of the SICAV prior to any subscription, or that may be obtained from the CNMV registries.

United Arab Emirates

The Fund is registered with the Securities and Commodities Authority ("SCA") of UAE as a foreign investment fund. The fund can be offered and marketed by licenced distributor who has individually obtained approval from SCA to distribute this Fund. The information on the list of licenced distributor for this fund will be available from the investment manager of the Fund.

U.K

Any financial promotion contained herein, as defined by UK regulations, has been approved by UTI International Limited (FCA no:183361); a firm authorised and regulated by the Financial Conduct Authority ("FCA") U.K. The Fund mentioned herein has been recognised by the FCA pursuant to section 264 of the FSMA. Facilities Agent is UTI International Limited,120 New Cavendish Street, London W1W 6XX, United Kingdom. Copies of the legal documents can be obtained in English, free of charge, from the Facilities Agent at 120 New Cavendish Street, London W1W 6XX, United Kingdom. The promotion of the Company in the United Kingdom can be carried out by persons authorized to carry on investment business in the United Kingdom under the FSMA and is not subject to the restrictions on promotion contained in section 238 of the FSMA. The FCA has not approved and takes no responsibility for the contents of the Prospectus or the UK Country Supplement or for any document referred to in them, nor for the financial soundness of the Fund or for the correctness of any statements made or expressed in the Prospectus or the UK Country Supplement or any document referred to in them.

United States of America

The Shares have not been nor will they be registered under the U.S. Securities Act of 1933, as amended (the "1933 Act"), or registered or qualified under the securities laws of any of the states of the United States. The Shares may not be offered, sold or delivered directly or indirectly in the United States or to or for the account or benefit of any "U.S. Person" (as defined in Regulation S under the 1933 Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the 1933 Act and any applicable state securities laws.

Neither the Company nor any Fund will be registered under the U.S. Investment Company Act of 1940, as amended (the "1940 Act"), pursuant to Section 3(c)(7) of the 1940 Act. Accordingly, Shares will only be sold to "U.S. Persons", as defined in Regulation S under the 1933 Act, who are "qualified purchasers", as defined in the 1940 Act or the regulations thereunder, or as otherwise consistent with Section 3(c)(7) of the 1940 Act.

Each subscriber for Shares that is a U.S. Person, as defined in Regulation S under the 1933 Act, will be required to certify that it is both an "accredited investor" as defined in Regulation D under the 1933 Act and a "qualified purchaser" as defined in Section 2(a)(51) of the 1940 Act or the regulations thereunder. The qualifications for an "accredited investor" and a "qualified purchaser" are set out in detail in Appendix III to this Prospectus.

Other jurisdictions

The distribution of this document of the Fund or Prospectus of the Fund and the offering of Shares of the Fund may be restricted in certain jurisdictions. This document or the Prospectus of the Fund does not constitute an offer or solicitation in any jurisdiction in which such offer or solicitation is not authorised or the person receiving the offer or solicitation may not lawfully do so. It is the responsibility of any person in possession of this document or the Prospectus of the Fund and of any person wishing to apply for Shares of the Fund to inform himself of and to observe all applicable laws and regulations of the countries of his nationality, residence, ordinary residence or domicile.

The Shares have not been approved or disapproved by the U.S. Securities and Exchange Commission (the "SEC") or any state securities commission, nor has any such regulatory authority passed upon or endorsed the merits of this offering or the accuracy or adequacy of this Prospectus. Any representation to the contrary is unlawful.

The Directors do not intend to permit Shares of any Fund of the Company acquired by investors subject to the United States Employee Retirement Income Security Act of 1974, as amended ("ERISA"), and by other benefit plan investors, as defined in ERISA, to equal or exceed 25% of the value of any such Class (determined in accordance with ERISA). Accordingly, each prospective applicant for Shares will be required to represent and warrant as to whether and to what extent he is a "benefit plan investor" for the purposes of ERISA.

For additional information on investments by U.S. Persons, including certain U.S. securities law, U.S. federal tax, and ERISA and other benefit plan considerations, please see Appendix III to this Prospectus.